Étude APEX : guselkumab et progression structurale dans le rhumatisme psoriasique actif
Référence : Mease PJ, Ritchlin CT, Coates LC, et al. Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24…